1-(3-chlorophenyl)piperazine has been researched along with Weight Gain in 4 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current therapeutic treatment for obesity is mostly focused on preventive measures involving dietary control and physical exercises in combination with anti-obesity medications." | 1.39 | Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. ( Cho, H; Cho, YS; Choi, GD; Choi, K; Im, HY; Jang, H; Kim, CH; Kim, YJ; Ko, M; Kwon, OS; Lee, J; Pae, AN; Park, WK; Seo, YW; Tae, J; Yang, HY, 2013) |
| " Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model." | 1.34 | Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor. ( Cao, X; Cullen, MJ; Devenny, J; Hung, CP; Janovitz, E; Keim, WJ; Lehman-McKeeman, L; Malley, MF; Malmstrom, SE; Miller, KJ; Narayanan, R; Pelleymounter, MA; Qu, Q; Robl, JA; Rohrbach, KW; Rossi, K; Thomas, MA; Ung, T; Varnes, JG; Wacker, DA; Wu, G; Zhang, G; Zuvich, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wacker, DA | 1 |
| Varnes, JG | 1 |
| Malmstrom, SE | 1 |
| Cao, X | 1 |
| Hung, CP | 1 |
| Ung, T | 1 |
| Wu, G | 1 |
| Zhang, G | 1 |
| Zuvich, E | 1 |
| Thomas, MA | 1 |
| Keim, WJ | 1 |
| Cullen, MJ | 1 |
| Rohrbach, KW | 1 |
| Qu, Q | 1 |
| Narayanan, R | 1 |
| Rossi, K | 1 |
| Janovitz, E | 1 |
| Lehman-McKeeman, L | 1 |
| Malley, MF | 1 |
| Devenny, J | 1 |
| Pelleymounter, MA | 1 |
| Miller, KJ | 1 |
| Robl, JA | 1 |
| Smith, BM | 1 |
| Smith, JM | 1 |
| Tsai, JH | 1 |
| Schultz, JA | 1 |
| Gilson, CA | 1 |
| Estrada, SA | 1 |
| Chen, RR | 1 |
| Park, DM | 1 |
| Prieto, EB | 1 |
| Gallardo, CS | 1 |
| Sengupta, D | 1 |
| Dosa, PI | 1 |
| Covel, JA | 1 |
| Ren, A | 1 |
| Webb, RR | 1 |
| Beeley, NR | 1 |
| Martin, M | 1 |
| Morgan, M | 1 |
| Espitia, S | 1 |
| Saldana, HR | 1 |
| Bjenning, C | 1 |
| Whelan, KT | 1 |
| Grottick, AJ | 1 |
| Menzaghi, F | 1 |
| Thomsen, WJ | 1 |
| Yang, HY | 1 |
| Tae, J | 1 |
| Seo, YW | 1 |
| Kim, YJ | 1 |
| Im, HY | 1 |
| Choi, GD | 1 |
| Cho, H | 1 |
| Park, WK | 1 |
| Kwon, OS | 1 |
| Cho, YS | 1 |
| Ko, M | 1 |
| Jang, H | 1 |
| Lee, J | 2 |
| Choi, K | 1 |
| Kim, CH | 1 |
| Pae, AN | 1 |
| Frank, GK | 1 |
| Kaye, WH | 1 |
| Weltzin, TE | 1 |
| Perel, J | 1 |
| Moss, H | 1 |
| McConaha, C | 1 |
| Pollice, C | 1 |
1 trial available for 1-(3-chlorophenyl)piperazine and Weight Gain
| Article | Year |
|---|---|
Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration.
Topics: Adolescent; Adult; Affect; Anorexia Nervosa; Body Image; Double-Blind Method; Female; Humans; Pipera | 2001 |
3 other studies available for 1-(3-chlorophenyl)piperazine and Weight Gain
| Article | Year |
|---|---|
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Blood-Brain Barrier; Cell Line; Conditioning, Op | 2007 |
Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzazepines; Cell Line; Eating; Humans; Inositol 1,4,5-Trisphosphate; | 2008 |
Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Area Under Curve; Azepines; Binding, Competitive; Dose-Response Relati | 2013 |